BLOOMFIELD, N.J., Nov. 28 /PRNewswire-FirstCall/ -- Alfacell Corporation , a biopharmaceutical company focused on the discovery, development and commercialization of novel ribonuclease (RNase) therapeutics for cancer and other life-threatening diseases, today announced that the Company has upgraded its current website at www.alfacell.com.
While some graphical modifications were made to the entire website, efforts to enhance the existing site were focused on the Investor Relations section. Many new features and components have been added to allow visitors access to a broader range of historical and contemporary data, and provides a new suite of tools to research and request information.
“We would like to invite all of our shareholders, industry observers following our clinical programs, and others interested in our Company to visit our upgraded website,” said Kuslima Shogen, Chairman and CEO of Alfacell.
About Alfacell Corporation
Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer, using its proprietary RNase technology platform. ONCONASE(R) (ranpirnase), Alfacell’s lead investigational drug candidate, is currently being evaluated in several studies, including a Phase IIIb registration study for malignant mesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC). For more information, please visit www.alfacell.com.
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the Company’s ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company’s periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Contact: Alfacell Corporation: Investor/Media Relations: Kuslima Shogen Elite Financial Communications Robert Love Dodi Handy (973) 748-8082 (407) 585-1080 info@alfacell.comacel@efcg.net
Alfacell Corporation
CONTACT: Kuslima Shogen, or Robert Love, both of Alfacell Corporation,+1-973-748-8082, info@alfacell.com; or Investor/Media Relations, Dodi Handyof Elite Financial Communications, +1-407-585-1080, acel@efcg.net, forAlfacell Corporation
Web site: http://www.alfacell.com/
